CO2017007135A2 - Derivados de pirazol[3,4-d] pirimidina y su uso para el tratamiento de leshmaniasis - Google Patents
Derivados de pirazol[3,4-d] pirimidina y su uso para el tratamiento de leshmaniasisInfo
- Publication number
- CO2017007135A2 CO2017007135A2 CONC2017/0007135A CO2017007135A CO2017007135A2 CO 2017007135 A2 CO2017007135 A2 CO 2017007135A2 CO 2017007135 A CO2017007135 A CO 2017007135A CO 2017007135 A2 CO2017007135 A2 CO 2017007135A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- leshmaniasis
- pyrazole
- pyrimidine derivatives
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El compuesto 3,3,3-trifluoro-N-((1,4-trans)-4-((3-((S)-2-metilmorfolino)-1H-pirazolo[3,4-d]pirimidin-6-il)amino)ciclohexil)propano-1-sulfonamida, que tiene la Fórmula (I): o una sal del mismo, su enantiómero opuesto, composiciones que comprenden el compuesto, y su uso en el tratamiento o prevención de leishmaniasis, en particular, leishmaniasis visceral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382011 | 2015-01-23 | ||
| PCT/EP2016/051240 WO2016116563A1 (en) | 2015-01-23 | 2016-01-21 | Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017007135A2 true CO2017007135A2 (es) | 2017-12-15 |
Family
ID=52395018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0007135A CO2017007135A2 (es) | 2015-01-23 | 2017-07-17 | Derivados de pirazol[3,4-d] pirimidina y su uso para el tratamiento de leshmaniasis |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10253028B2 (es) |
| EP (1) | EP3247713B1 (es) |
| JP (1) | JP6625649B2 (es) |
| KR (1) | KR102572178B1 (es) |
| CN (1) | CN107406452B (es) |
| AR (1) | AR103474A1 (es) |
| AU (1) | AU2016208528B2 (es) |
| BR (1) | BR112017015828B1 (es) |
| CA (1) | CA2973432C (es) |
| CL (1) | CL2017001857A1 (es) |
| CO (1) | CO2017007135A2 (es) |
| CR (1) | CR20170339A (es) |
| DO (1) | DOP2017000167A (es) |
| EA (1) | EA032763B1 (es) |
| ES (1) | ES2754803T3 (es) |
| IL (1) | IL253427B (es) |
| MX (1) | MX2017009525A (es) |
| MY (1) | MY190895A (es) |
| PE (1) | PE20180020A1 (es) |
| PH (1) | PH12017501307B1 (es) |
| SG (1) | SG11201705626QA (es) |
| TW (1) | TWI726861B (es) |
| UA (1) | UA120385C2 (es) |
| UY (1) | UY36525A (es) |
| WO (1) | WO2016116563A1 (es) |
| ZA (1) | ZA201704586B (es) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6706754B2 (en) * | 2000-11-06 | 2004-03-16 | The United States Of America As Represented By The Secretary Of The Army | Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis |
| US7405220B2 (en) | 2004-06-09 | 2008-07-29 | Hoffmann-La Roche Inc. | Pyrazolopyrimidines |
| EP1880791A1 (en) | 2006-07-21 | 2008-01-23 | Aleris Aluminum Koblenz GmbH | Process and apparatus for laser joining two components through the use of a laminar inert gas flow coaxial to a metal filler wire |
| WO2008039359A2 (en) * | 2006-09-25 | 2008-04-03 | Janssen Pharmaceutica N.V. | Bicyclic pyrimidine kinase inhibitors |
| KR20090103897A (ko) * | 2006-12-28 | 2009-10-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 피라졸로피리미딘 화합물 |
| AU2008211108A1 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-h-pyrazolo (3,4b) pyrimidine derivatives and their use as modulators of mitotic kinases |
| ES2647163T3 (es) * | 2008-01-04 | 2017-12-19 | Intellikine, Inc. | Derivados de isoquinolinona sustituidos con una purina útiles como inhibidores de la PI3K |
| PL2285808T3 (pl) * | 2008-04-29 | 2014-04-30 | Novartis Ag | Spiro-indolowe pochodne do leczenia chorób pasożytniczych |
| MX2011008444A (es) * | 2009-02-12 | 2011-09-06 | Astellas Pharma Inc | Derivado de heteroanillo. |
| HUE034503T2 (en) * | 2009-07-02 | 2018-02-28 | Sanofi Sa | 2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine |
| RU2607453C2 (ru) * | 2009-12-04 | 2017-01-10 | Сенхва Байосайенсиз, Инк. | Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы |
| PT3527563T (pt) * | 2013-03-12 | 2021-12-09 | Vertex Pharma | Inibidores de adn-pk |
-
2016
- 2016-01-21 EP EP16701304.4A patent/EP3247713B1/en active Active
- 2016-01-21 UY UY0001036525A patent/UY36525A/es unknown
- 2016-01-21 MY MYPI2017702657A patent/MY190895A/en unknown
- 2016-01-21 CA CA2973432A patent/CA2973432C/en active Active
- 2016-01-21 CR CR20170339A patent/CR20170339A/es unknown
- 2016-01-21 AR ARP160100161A patent/AR103474A1/es active IP Right Grant
- 2016-01-21 BR BR112017015828-0A patent/BR112017015828B1/pt active IP Right Grant
- 2016-01-21 ES ES16701304T patent/ES2754803T3/es active Active
- 2016-01-21 US US15/545,193 patent/US10253028B2/en active Active
- 2016-01-21 WO PCT/EP2016/051240 patent/WO2016116563A1/en active Application Filing
- 2016-01-21 AU AU2016208528A patent/AU2016208528B2/en active Active
- 2016-01-21 PE PE2017001252A patent/PE20180020A1/es unknown
- 2016-01-21 EA EA201791658A patent/EA032763B1/ru not_active IP Right Cessation
- 2016-01-21 JP JP2017538715A patent/JP6625649B2/ja active Active
- 2016-01-21 CN CN201680007020.9A patent/CN107406452B/zh active Active
- 2016-01-21 UA UAA201708634A patent/UA120385C2/uk unknown
- 2016-01-21 TW TW105101811A patent/TWI726861B/zh active
- 2016-01-21 KR KR1020177023322A patent/KR102572178B1/ko active IP Right Grant
- 2016-01-21 SG SG11201705626QA patent/SG11201705626QA/en unknown
- 2016-01-21 MX MX2017009525A patent/MX2017009525A/es active IP Right Grant
-
2017
- 2017-07-07 ZA ZA2017/04586A patent/ZA201704586B/en unknown
- 2017-07-11 IL IL253427A patent/IL253427B/en active IP Right Grant
- 2017-07-17 CO CONC2017/0007135A patent/CO2017007135A2/es unknown
- 2017-07-18 CL CL2017001857A patent/CL2017001857A1/es unknown
- 2017-07-19 PH PH12017501307A patent/PH12017501307B1/en unknown
- 2017-07-21 DO DO2017000167A patent/DOP2017000167A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
| CL2016002970A1 (es) | Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo. | |
| BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
| ECSP18082774A (es) | Derivados aromáticos de sulfonamida | |
| BR112018075140A2 (pt) | composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8 | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| EP3307738A4 (en) | ARYL-DIHYDRO-2H-BENZO [B] [1,4] OXAZINE-SULPHONAMIDE AND RELATED COMPOUNDS FOR USE AS AGENTS OF RORY AND FOR THE TREATMENT OF DISEASES | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CR20170425A (es) | Nuevas proteínas específicas para pioverdina y pioquelina | |
| EA201791467A1 (ru) | Водный офтальмологический раствор | |
| EP3292119A4 (en) | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| MY180727A (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease | |
| CO2017007135A2 (es) | Derivados de pirazol[3,4-d] pirimidina y su uso para el tratamiento de leshmaniasis | |
| PH12019500237A1 (en) | New use of n,n-bis-2-mercaptoethyl isophthalamide | |
| WO2019040104A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES | |
| MX2019007786A (es) | Compuestos sustituidos de guanidina. | |
| BR112018002138A2 (pt) | composto 2-(5 s-metil-2-oxo-4r-fenil-pirrolidin-1-il)-acetamida, uso, composição farmacêutica e método para a profilaxia ou o tratamento de convulsões | |
| AR112040A1 (es) | Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen |